Astrazeneca (AZN) Depreciation & Amortization (CF) (2009 - 2026)

Astrazeneca's Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 6.39% year-over-year to $1.4 billion; the TTM figure through Jun 2026 stood at $4.4 billion (down 35.17% YoY), while the FY2025 annual figure was $5.7 billion, down 14.28% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $1.4 billion, down from $1.5 billion in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $4.1 billion in Q4 2023, with the low at $1.3 billion in Q1 2024.
• The 5-year median for Depreciation & Amortization (CF) is $1.4 billion (2025), against an average of $1.8 billion.
• The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) soared 107.87% in 2022, then tumbled 42.44% in 2024.
• Astrazeneca's Depreciation & Amortization (CF) stood at $4.0 billion in 2022, then gained by 1.5% to $4.1 billion in 2023, then plunged by 42.44% to $2.3 billion in 2024, then tumbled by 35.34% to $1.5 billion in 2025, then slipped by 9.6% to $1.4 billion in 2026.
• Business Quant data shows AZN's Depreciation & Amortization (CF) at $1.4 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.5 billion in Q3 2025.